© Globe Newswire
25.06.2024
SKYE
LISTED
NASDAQ
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
News Preview
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will participate in the Piper Sa...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
EVT
LISTED
XETR
Just – Evotec Biologics vom US-amerikanischen Verteidigungsministerium für Manufacturing Optimization Program ausgewählt
News Preview
Just – Evotec Biologics wird eine ultraschnelle, kosteneffiziente Plattformlösung für die Herstellung von Biotherapeutika für das Manufacturing Optimization Program des US-amerikanischen Verteidigungsministeriums liefern
Die Produktionslösung umfasst die nahtlose Integration der beschleunigten Entwicklung von mAb-Wirkstoffen in das Manu......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
EVT
LISTED
XETR
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
News Preview
Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program
Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program
Manufacturing Optimization P......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
24.06.2024
ASND
LISTED
NASDAQ
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
News Preview
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
24.06.2024
MRK
LISTED
XETR
Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
News Preview
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2024
MRK
LISTED
XETR
Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
News Preview
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2024
MRK
LISTED
XETR
Phase-III-Studien mit Xevinapant in lokal fortgeschrittenen Kopf-Hals-Tumoren eingestellt
News Preview
Veröffentlichung von Insiderinformationen nach Art. 17 der Verordnung (EU) Nr. 596/2014
Merck KGaA: Phase-III-Studien mit Xevinapant in lokal fortgeschrittenen Kopf-Hals-Tumoren eingestellt
Darmstadt, 24. Juni 2024: Merck KGaA untersucht eine Behandlung mit Xevinapant in Kombination mit platinbasierter Chemotherapie (CRT) im Vergleich zu Placebo......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2024
GMAB
LISTED
CPH
Transactions in Connection with Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
News Preview
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2024
NSIS B
LISTED
CPH
Major shareholder announcement
News Preview
June 21, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
ZEAL
LISTED
CPH
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
News Preview
Company announcement – No. 32 / 2024...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.06.2024
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
News Preview
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial r...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2024
ILM1
LISTED
XETR
Erfolgreiche Umplatzierung der Aktien von Firmengründer Manfred Schneider an Luxempart S.A.
News Preview
Pressemitteilung
Medios AG: Erfolgreiche Umplatzierung der Aktien von Firmengründer Manfred Schneider an Luxempart S.A.
Berlin, 20. Juni 2024 – Medios, ein führender Anbieter von Specialty Pharma in Europa, wurde heute darüber informiert, dass Manfred Schneider seinen gesamten Aktienbesitz an der Medios AG umplatziert hat. Schneiders Aktien, d......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2024
ILM1
LISTED
XETR
Erfolgreiche Umplatzierung der Aktien von Firmengründer Manfred Schneider an Luxempart S.A.
News Preview
Pressemitteilung
Medios AG: Erfolgreiche Umplatzierung der Aktien von Firmengründer Manfred Schneider an Luxempart S.A.
Berlin, 20. Juni 2024 – Medios, ein führender Anbieter von Specialty Pharma in Europa, wurde heute darüber informiert, dass Manfred Schneider seinen gesamten Aktienbesitz an der Medios AG umplatziert hat. Schneiders Aktien, d......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2024
ILM1
LISTED
XETR
Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A.
News Preview
Press Release
Medios AG: Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A.
Berlin, June 20, 2024 – Medios, a leading provider of Specialty Pharma in Europe, was today informed that Manfred Schneider has reallocated all of his shares in Medios AG. Schneider’s shares, which corresponds to a total of 14.9% of Medios’......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
News Preview
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disordersat the FOCIS Annual Meeting, San Francisco (June 18 – 21)...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.06.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
News Preview
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.06.2024
EUZ
LISTED
XETR
Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
News Preview
June 19, 2024 – Berlin, Germany and Řež, Czech Republic – Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated ......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.06.2024
EUZ
LISTED
XETR
Eckert & Ziegler und UJF eröffnen hochmoderne Actinium-225 Produktionsanlage
News Preview
19. Juni 2024 - Berlin, Deutschland und Řež, Tschechische Republik - Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) gibt in Zusammenarbeit mit dem Institut für Kernphysik der Tschechischen Akademie der Wissenschaften (Ústav jaderné fyziky, "UJF") die feierliche Eröffnung einer wegweisenden Actinium-225 (Ac-225) Produktionsanlage b......
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2024
INDV
LISTED
NASDAQ
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Ca
News Preview
Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a single IN dose of OPVEE compared to a single dose of IN naloxone. Across scenarios of fentanyl or carfentanil overdoses, simultaneous administration of four doses of IN naloxone (4×4 mg) was needed...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
COPN
LISTED
SIX
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
News Preview
Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innov...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
ATNM
LISTED
XASE
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE American:...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
EAPI
LISTED
EURONEXT
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
News Preview
Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. Priothera is headquartered in Dublin, Ireland, and has a subsidiary...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
GNFT
LISTED
EURONEXT
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in th...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
NSIS B
LISTED
CPH
The era of biosolutions. Outlook upgraded for 2024
News Preview
Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%....
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2024
ATNM
LISTED
XASE
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featurin...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
BAVA
LISTED
CPH
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
News Preview
COPENHAGEN, Denmark, June 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya v...
Themefolio
Profiler
Peergroup
© PR Newswire
17.06.2024
ATNM
LISTED
XASE
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
News Preview
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors
- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy
- Menin combination expands ba...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
GMAB
LISTED
CPH
Transactions in Connection with Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2024
AFX
LISTED
XETR
Prognose für Geschäftsjahr 2023/24 für Umsatz und EBIT aufgrund langsamer als erwarteter Erholung des Gerätegeschäfts reduziert
News Preview
Prognose für Geschäftsjahr 2023/24 für Umsatz und EBIT aufgrund langsamer als erwarteter Erholung des Gerätegeschäfts reduziert
Jena, 17. Juni 2024
In den ersten 8 Monaten des Geschäftsjahres 2023/24 zum 31. Mai 2024 erzielte die Carl Zeiss Meditec AG (ISIN: DE0005313704) ohne den Beitrag aus dem Erwerb von Dutch Ophthalmic Research Cent......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2024
AFX
LISTED
XETR
Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
News Preview
Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
Jena, June 17, 2024
In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2024
AFX
LISTED
XETR
Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
News Preview
Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
Jena, June 17, 2024
In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
GLPG
LISTED
EURONEXT
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
News Preview
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congres...
Themefolio
Profiler
Peergroup
© PR Newswire
14.06.2024
ATNM
LISTED
XASE
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
News Preview
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial
- Long-term efficacy results in patients with active relapsed or refractory acute...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2024
1SXP
LISTED
XETR
SCHOTT Pharma eröffnet hochmoderne Produktionsstätte im ungarischen Lukácsháza
News Preview
Erweiterung der Produktion von vorfüllbaren Glasspritzen: SCHOTT Pharma eröffnet hochmoderne Produktionsstätte im ungarischen Lukácsháza
11. Juni 2024, Lukácsháza, Ungarn
Nach einer Investition von 76 Millionen Euro (28,044 Milliarden HUF) und eineinhalb Jahren Bauzeit eröffnet SCHOTT Pharma seine neueste Produktionsstätte in Lukácsháza, Unga......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2024
1SXP
LISTED
XETR
SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary
News Preview
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary
June 11, 2024, Lukácsháza, Hungary
After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens its newest production facility in Lukácsháza, Hungary
Expanding production capacity ......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
ORY
LISTED
BME
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
News Preview
MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents preliminary data from its ongoing Phase Ib FRIDA study investigating iadademstat in c...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
News Preview
Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
FYB
LISTED
XETR
Formycon reports on the results of the Annual General Meeting
News Preview
Press Release // June 13, 2024
Formycon reports on the results of the Annual General Meeting
Management provides detailed report on financial year 2023 and current company performance
Shareholders approve all agenda items and formally approve the acts of the members of the Management Board and Supervisory Board by large majority
Supervisory Boa......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
FYB
LISTED
XETR
Formycon informiert über die Ergebnisse der ordentlichen Hauptversammlung
News Preview
Pressemitteilung // 13. Juni 2024
Formycon informiert über die Ergebnisse der ordentlichen Hauptversammlung
Vorstand berichtet ausführlich über Geschäftsjahr 2023 und aktuelle Unternehmensentwicklung
Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu und entlasten Vorstand sowie Aufsichtsrat mit jeweils großer Mehrheit
Aufsichtsr......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2024
ZEAL
LISTED
CPH
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
News Preview
Company announcement – No. 31 / 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to Formycon AG
Company Name: Formycon AG
ISIN: DE000A1EWVY8
Reason for the research: Update
Recommendation: Buy
from: 13.06.2024
Target price: €80,00
Target price on sight of: 12 months
Last rating change: -
Analyst: Simon Sc......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
FYB
LISTED
XETR
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
News Preview
Press Release // June 13, 2024
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In).
"Dah......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
FYB
LISTED
XETR
Formycon startet klinisches Programm für FYB206, einen Biosimilar-Kandidaten für das immun-onkologische Blockbuster-Medikament Keytruda®
News Preview
Pressemitteilung // 13. Juni 2024
Formycon startet klinisches Programm für FYB206, einen Biosimilar-Kandidaten für das immun-onkologische Blockbuster-Medikament Keytruda®
Erster Patient in klinische Phase-I-Studie „Dahlia“ zum Vergleich der Pharmakokinetik (PK), Sicherheit und Verträglichkeit von FYB206 mit dem Referenzarzneimittel Keytruda®[i] e......
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
QGEN
LISTED
NYSE
QIAGEN veröffentlicht Nachhaltigkeitsbericht 2023 und hebt Fortschritte bei ESG-Zielen sowie Engagement für nachhaltiges Wachstum hervor
News Preview
ESG-Engagement wird als strategische Geschäftsinvestition angesehen, die für Stakeholder wie Kunden und Mitarbeitende Mehrwert schafft // Umwelt: Reduktion der Scope-1- und Scope-2-Emissionen im Jahr 2023 um 15% durch Einkauf von grünem Strom , Plastikverbrauch um 7% reduziert // Soziales: // QIAGEN erweitert weltweiten Zugang zu Diagnostika durch...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
News Preview
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
News Preview
STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead candidate drug BSG005 in patients with invasive fungal infections in India....
Themefolio
Profiler
Peergroup
© EQS Newswire
12.06.2024
EVT
LISTED
XETR
Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
News Preview
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research
Hamburg, Germany, 12 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today th......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.06.2024
EVT
LISTED
XETR
Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
News Preview
Wichtiger wissenschaftlicher Fortschritt stärkt die gemeinsame Pipeline der strategischen Neurologie-Partnerschaft mit Bristol Myers Squibb und löst eine Zahlung von 20 Mio. US$ an Evotec aus, um die weitere Forschung voranzutreiben
Hamburg, 12. Juni 2024:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE000566480......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
QGEN
LISTED
NYSE
QIAGEN führt neue QIAcuity digitale PCR-Assays für mikrobielle Anwendungen zur Erforschung und Überwachung von Infektionskrankheiten ein
News Preview
35 neue laborvalidierte dPCR Microbial DNA Detection Assays auf Forschungsplattform GeneGlobe verfügbar, die eine Vielzahl an Erregern von tropischen Krankheiten, sexuell übertragbaren Infektionen und Harnweginfektionen nachweisen // Die QIAcuity digitale PCR-Technologie ermöglicht eine präzise und sensitive Pathogenerkennung und unterstützt damit...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
GMAB
LISTED
CPH
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.06.2024
SOON
LISTED
SIX
Sonova Aktionäre stimmen allen Anträgen des Verwaltungsrates zu
News Preview
Sonova Holding AG
/ Schlagwort(e): Generalversammlung
Ordentliche Generalversammlung 2024:
Sonova Aktionäre stimmen allen Anträgen des Verwaltungsrates zu
11.06.2024 / 18:04 CET/CEST
Medienmitteilung
Stäfa (Schweiz), 11. Juni 2024 – Sonova Holding AG, ein führender Anbieter von Hörlösungen, teilt das Ergebnis der Abstim......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.06.2024
SOON
LISTED
SIX
Sonova Aktionäre stimmen allen Anträgen des Verwaltungsrates zu
News Preview
Sonova Holding AG
/ Schlagwort(e): Generalversammlung
Ordentliche Generalversammlung 2024:
Sonova Aktionäre stimmen allen Anträgen des Verwaltungsrates zu
11.06.2024 / 18:04 CET/CEST
Medienmitteilung
Stäfa (Schweiz), 11. Juni 2024 – Sonova Holding AG, ein führender Anbieter von Hörlösungen, teilt das Ergebnis der Abstim......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.06.2024
SOON
LISTED
SIX
Sonova shareholders approve all motions of the Board of Directors
News Preview
Sonova Holding AG
/ Key word(s): AGMEGM
Annual General Shareholders’ Meeting 2024:
Sonova shareholders approve all motions of the Board of Directors
11.06.2024 / 18:04 CET/CEST
Media Release
Stäfa (Switzerland), June 11, 2024 – Sonova Holding AG, a leading provider of hearing care solutions, announces the results of the......
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2024
ATNM
LISTED
XASE
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
News Preview
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia
- Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and vene...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
POAI
LISTED
NASDAQ
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
News Preview
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
GN
LISTED
CPH
GN to gradually wind-down its Elite and Talk product lines. Strong performance in the Hearing division to partly off-set the extraordinary impact from the gradual wind-down
News Preview
Today, GN has decided to gradually wind-down its Elite and Talk product lines to further increase focus and resources on more attractive parts of GN’s business....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
GNFT
LISTED
EURONEXT
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a historic corporate milestone: the U.S. Food and Dr...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
